ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY
Clinical trials for ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY trials appear
Sign up with your email to follow new studies for ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for babies with rare calcification disease: experimental drug enters human testing
Disease control Recruiting nowThis study tests an experimental drug called INZ-701 in 16 infants (up to 1 year old) with rare genetic conditions (ENPP1 or ABCC6 deficiency) that cause dangerous calcium buildup in blood vessels and other tissues. The main goal is to check the drug's safety and how the body pro…
Matched conditions: ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY
Phase: PHASE1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for babies with rare bone and heart disease: experimental drug enters final testing
Disease control Recruiting nowThis study tests a new medicine called INZ-701 in babies up to 1 year old who have a rare genetic condition called ENPP1 deficiency. The disease can cause serious heart and bone problems. The goal is to see if the medicine can raise certain blood levels, improve survival, and pro…
Matched conditions: ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY
Phase: PHASE3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated May 07, 2026 18:44 UTC